Argos Therapeutics Presents New Phase 2 Data Showing its Arcelis ... - PR Newswire (press release) PDF Print
PR Newswire (press release)
DURHAM, NC, June 5, 2011 /PRNewswire/ -- Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.